Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer

Table 4 Univariate and multivariate analyses of progression free survival in patients

Characteristic		GEM + IRE group (n = 33)			GEM group (n = 35)
		Univariate analysis			Multivariate analysis
		HR	95%CI	P value	HR	95%CI	P value
Age (yr)	≤ 60/> 60	1.167	0.669-2.203	0.554
Gender	Female/male	1.602	0.942-2.802	0.097
Tumor size (cm)	≤ 4/> 4	0.787	0.489-1.280	0.334
Tumor site	Head/body/tail	0.942	0.623-1.410	0.750
Tumor volume (cm3)	≤ 37/> 37	2.386	1.298-4.406	0.012	2.856	1.180-6.420	0.025
WBC (× 109)	≤ 10/> 10	1.149	0.468-2.575	0.697
HGB (g/L)	≤ 120/> 120	0.587	0.298-1.513	0.285
PLT (× 109)	≤ 300/> 300	0.653	0.274-1.752	0.342
ALT (U/L)	≤ 40/> 40	0.542	0.433-1.533	0.341
AST (U/L)	≤ 40/> 40	0.636	0.347-1.521	0.304
ALP (U/L)	≤ 100/> 100	0.726	0.521-1.367	0.572
CEA (ng/mL)	≤ 5/> 5	1.322	0.715-2.602	0.162
CA19-9 (U/ml)	≤ 35/> 35	2.056	1.009-3.019	0.052
CA19-9 decrease 3 mo after IRE	≤ 50%/> 50%	2.258	0.895-6.428	0.032
GEM	With/without IRE	0.557	0.308-1.210	0.046	0.582	0.322-1.050	0.042

IRE: Irreversible electroporation; GEM: Gemcitabine; HR: Hazard ratio; WBC: White blood cell count; HGB: Hemoglobin; PLT: Platelet count; ALT: Alanine transaminase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9.